Post-earnings recap
Reported
Mon, Nov 14, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.7%
Crinetics Pharmaceuticals reported a loss per share of $0.78, which met expectations, but did not provide revenue figures. The stock saw a slight increase of 0.22%, indicating that investors may be focusing on the company's long-term potential rather than short-term earnings. The lack of guidance may lead to uncertainty among investors as they assess future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.78 | N/A | +0.00% |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to advancing their pipeline. However, they did not provide specific updates or guidance for future performance.
Management did not provide specific revenue figures or guidance for future quarters.
The focus remains on ongoing clinical trials and product development.